HRP20191864T1 - Imunogeni pripravci protiv bakterije clostridium difficile - Google Patents
Imunogeni pripravci protiv bakterije clostridium difficile Download PDFInfo
- Publication number
- HRP20191864T1 HRP20191864T1 HRP20191864TT HRP20191864T HRP20191864T1 HR P20191864 T1 HRP20191864 T1 HR P20191864T1 HR P20191864T T HRP20191864T T HR P20191864TT HR P20191864 T HRP20191864 T HR P20191864T HR P20191864 T1 HRP20191864 T1 HR P20191864T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- immunogenic preparation
- clostridium difficile
- toxin
- isolated
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 13
- 241000193163 Clostridioides difficile Species 0.000 title claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 231100000654 protein toxin Toxicity 0.000 claims 4
- 101710182223 Toxin B Proteins 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 1
- 101710182532 Toxin a Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (9)
1. Imunogeni pripravak, naznačen time što sadrži fuzijski protein koji sadrži (i) protein CDTa pune duljine i (ii) protein CDTb, gdje je protein CDTb protein CDTb pune duljine s uklonjenom prodomenom.
2. Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što fuzijski protein, naznačen time što sadrži protein CDTa pune duljine, a protein CDTb je pogodno ili sadrži:
(i) SEQ ID NO: 14; ili
(ii) varijanta fuzijskog proteina čiji slijed je najmanje 80%, 85%, 88%, 90%, 92%, 95%, 98%, 99%, 100% istovjetan SEQ ID NO: 14; ili
(iii) fragment koji ima najmanje 30, 50, 80, 100, 120, 150, 200, 250, 300, 350 ili 400 uzastopnih aminokiselina iz SEQ ID NO: 14.
3. Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pripravak potiče stvaranje protutijela koja neutraliziraju CDTa ili CDTb ili oba.
4. Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pripravak potiče stvaranje protutijela koja neutraliziraju binarni toksin.
5. Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što imunogeni pripravak dodatno sadrži izolirani protein toksina A iz bakterije Clostridium difficile i/ili izolirani protein toksina B iz bakterije Clostridium difficile.
6. Imunogeni pripravak u skladu s patentnim zahtjevom 5, naznačen time što imunogeni pripravak sadrži izolirani protein toksina A iz bakterije Clostridium difficile i izolirani protein toksina B iz bakterije Clostridium difficile, gdje izolirani protein toksina A iz bakterije Clostridium difficile i izolirani protein toksina B iz bakterije Clostridium difficile tvore fuzijski protein.
7. Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što imunogeni pripravak dodatno sadrži adjuvans.
8. Cjepivo, naznačeno time što sadrži imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, kao i farmaceutski prihvatljivu pomoćnu tvar.
9. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-7 ili cjepivo u skladu s patentnim zahtjevom 8, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju bolesti uzrokovanom bakterijom C. difficile.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411306.2A GB201411306D0 (en) | 2014-06-25 | 2014-06-25 | Immunogenic composition |
| GB201411371A GB201411371D0 (en) | 2014-06-26 | 2014-06-26 | Immunogenic composition |
| PCT/EP2015/064324 WO2015197737A1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
| EP15733404.6A EP3160500B1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191864T1 true HRP20191864T1 (hr) | 2020-01-10 |
Family
ID=53498986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191864TT HRP20191864T1 (hr) | 2014-06-25 | 2019-10-15 | Imunogeni pripravci protiv bakterije clostridium difficile |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20170218031A1 (hr) |
| EP (2) | EP3160500B1 (hr) |
| JP (2) | JP6688233B2 (hr) |
| CN (1) | CN106536544B (hr) |
| BE (1) | BE1022949B1 (hr) |
| BR (1) | BR112016030096B1 (hr) |
| CA (1) | CA2952118A1 (hr) |
| CY (1) | CY1122145T1 (hr) |
| DK (1) | DK3160500T3 (hr) |
| ES (1) | ES2749701T3 (hr) |
| HR (1) | HRP20191864T1 (hr) |
| HU (1) | HUE045936T2 (hr) |
| LT (1) | LT3160500T (hr) |
| MX (1) | MX2016017094A (hr) |
| PL (1) | PL3160500T3 (hr) |
| PT (1) | PT3160500T (hr) |
| SI (1) | SI3160500T1 (hr) |
| WO (1) | WO2015197737A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3595709A4 (en) * | 2017-03-15 | 2020-12-23 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE |
| CN112703006A (zh) | 2018-06-19 | 2021-04-23 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| EP0362278A4 (en) | 1987-06-05 | 1990-05-14 | Us Health | FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER. |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| PL170980B1 (pl) | 1992-06-25 | 1997-02-28 | Smithkline Beecham Biolog | Szczepionka PL PL PL PL PL PL PL |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| NZ295998A (en) | 1994-10-24 | 1999-10-28 | Ophidian Pharm Inc | Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP0832282A1 (en) | 1995-06-02 | 1998-04-01 | Incyte Pharmaceuticals, Inc. | IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES |
| JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| US20020065396A1 (en) | 2000-03-28 | 2002-05-30 | Fei Yang | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| WO2005004791A2 (en) * | 2002-11-08 | 2005-01-20 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
| AU2012349753A1 (en) * | 2011-12-08 | 2014-06-19 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| SI2928489T1 (sl) * | 2012-12-05 | 2019-05-31 | Glaxosmithkline Biologicals S.A. | Imunogeni sestavek |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2015
- 2015-06-25 CN CN201580039744.7A patent/CN106536544B/zh active Active
- 2015-06-25 ES ES15733404T patent/ES2749701T3/es active Active
- 2015-06-25 JP JP2016575190A patent/JP6688233B2/ja active Active
- 2015-06-25 HU HUE15733404A patent/HUE045936T2/hu unknown
- 2015-06-25 EP EP15733404.6A patent/EP3160500B1/en active Active
- 2015-06-25 LT LT15733404T patent/LT3160500T/lt unknown
- 2015-06-25 EP EP19192151.9A patent/EP3636278A3/en not_active Withdrawn
- 2015-06-25 BE BE2015/5390A patent/BE1022949B1/fr active
- 2015-06-25 BR BR112016030096-3A patent/BR112016030096B1/pt active IP Right Grant
- 2015-06-25 WO PCT/EP2015/064324 patent/WO2015197737A1/en active Application Filing
- 2015-06-25 US US15/320,190 patent/US20170218031A1/en not_active Abandoned
- 2015-06-25 SI SI201530954T patent/SI3160500T1/sl unknown
- 2015-06-25 MX MX2016017094A patent/MX2016017094A/es active IP Right Grant
- 2015-06-25 PT PT157334046T patent/PT3160500T/pt unknown
- 2015-06-25 DK DK15733404T patent/DK3160500T3/da active
- 2015-06-25 PL PL15733404T patent/PL3160500T3/pl unknown
- 2015-06-25 CA CA2952118A patent/CA2952118A1/en active Pending
-
2019
- 2019-10-09 CY CY20191101061T patent/CY1122145T1/el unknown
- 2019-10-15 HR HRP20191864TT patent/HRP20191864T1/hr unknown
-
2020
- 2020-01-17 JP JP2020005532A patent/JP2020100625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BE1022949B1 (fr) | 2016-10-21 |
| JP6688233B2 (ja) | 2020-04-28 |
| CA2952118A1 (en) | 2015-12-30 |
| PL3160500T3 (pl) | 2020-02-28 |
| EP3160500A1 (en) | 2017-05-03 |
| BE1022949A1 (fr) | 2016-10-21 |
| ES2749701T3 (es) | 2020-03-23 |
| BR112016030096A2 (pt) | 2017-08-22 |
| EP3636278A2 (en) | 2020-04-15 |
| EP3160500B1 (en) | 2019-08-21 |
| MX2016017094A (es) | 2017-05-03 |
| WO2015197737A1 (en) | 2015-12-30 |
| US20170218031A1 (en) | 2017-08-03 |
| LT3160500T (lt) | 2019-10-25 |
| JP2020100625A (ja) | 2020-07-02 |
| PT3160500T (pt) | 2019-11-11 |
| CN106536544A (zh) | 2017-03-22 |
| CN106536544B (zh) | 2020-04-07 |
| JP2017520573A (ja) | 2017-07-27 |
| BR112016030096A8 (pt) | 2021-07-06 |
| EP3636278A3 (en) | 2020-07-15 |
| DK3160500T3 (da) | 2019-11-11 |
| HUE045936T2 (hu) | 2020-01-28 |
| CY1122145T1 (el) | 2020-11-25 |
| SI3160500T1 (sl) | 2019-11-29 |
| BR112016030096B1 (pt) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191291T1 (hr) | Imunogeni pripravak | |
| HRP20200727T1 (hr) | Pripravci i metode povezane s varijantama proteina a (spa) | |
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
| EA201890355A1 (ru) | Новые способы индукции иммунного ответа | |
| HRP20161608T1 (hr) | Modificirani tuberkulozni antigeni | |
| GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
| SI2707393T1 (en) | Fusion proteins and combined vaccines comprising protein E and AH haemophilus influenzae | |
| WO2015181356A8 (en) | Vaccine composition against streptococcus suis infection | |
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| HRP20211926T1 (hr) | Konstrukti proteina uspa2 i njihova upotreba | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| PE20220960A1 (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros | |
| PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| MX2018005462A (es) | Composiciones inmunogénicas de rsv quimérico y métodos de uso. | |
| WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
| WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
| WO2018066999A3 (en) | Chimeric enterovirus virus-like particles | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| WO2012174455A3 (en) | Group a streptococcus multivalent vaccine |